Concentrations of insulin-like growth factor I and steroids in follicular fluid of preovulatory bovine ovarian follicles: effect of daily injections of a growth hormone-releasing factor analog and(or) thyrotropin-releasing hormone.
Spicer. L J LJ; Enright. W J WJ
Key Findings
- GRF‑1‑29 did not alter follicular fluid IGF‑I levels in cows.
- GRF‑1‑29 modestly increased the size of large ovarian follicles.
- GRF‑1‑29 raised progesterone concentrations in medium‑sized follicles; TRH had no impact on steroid levels.
Practical Outcomes
- For biohackers, this animal data suggests GRF‑1‑29 might influence ovarian follicle growth and progesterone production, but the findings are limited to cattle and may not translate to humans. No clear protocol for human use emerges, and safety or dosing information for people is lacking. Until human studies are available, applying this peptide for longevity or performance goals is not recommended.
Summary
In a study on young cows, daily injections of a growth‑hormone‑releasing peptide (GRF‑1‑29) for almost three months did not change the amount of IGF‑I in the fluid around ovarian follicles, but it made the biggest follicles a bit larger and raised progesterone levels in medium‑sized follicles. Thyrotropin‑releasing hormone had no effect.
Abstract
To determine whether long-term administration of growth hormone (GH)-releasing factor (GRF) and(or) thyrotropin-releasing hormone (TRH) alters ovarian follicular fluid (FFL) concentrations of insulin-like growth factor-I (IGF-I), progesterone, and estradiol (E2), and follicular growth, Friesian x Hereford heifers (n = 47; 346 +/- 3 kg) were divided into the following four groups: control (vehicle; n = 11); 1 micrograms GRF (human [Des NH2 Tyr1, D-Ala2, Ala15] GRF [1-29]-NH2).kg-1 BW.d-1 (n = 12); 1 microgram TRH.kg-1 BW.d-1 (n = 12); or GRF + TRH (n = 12). Daily injections (s.c.) continued for 86 d. On d 89, heifers that had been synchronized were slaughtered and ovaries were removed. Follicles were grouped by magnitude of diameter into the three following sizes: 1 to 3.9 mm (small, n = 55), 4.0 to 7.9 mm (medium, n = 63), and greater than or equal to 8 mm (large, n = 71). Growth hormone-releasing factor and(or) TRH did not affect (P greater than .10) IGF-I concentrations in FFL of any follicle size group. Growth hormone-releasing factor increased (P less than .06) size (means +/- pooled SE) of large follicles (14.7 vs 13.0 +/- .6 mm). Growth hormone-releasing factor also increased (P less than .05) progesterone concentrations 4.4-fold above controls in FFL of medium-sized follicles but had no effect on progesterone in FFL of the small or large follicles. Thyrotropin-releasing hormone did not alter FFL progesterone or E2 concentrations in any follicle size group. We conclude that the GRF and(or) TRH treatments we employed did not affect intra-ovarian IGF-I concentrations, but GRF may alter steroidogenesis of medium-sized follicles and growth of large follicles.
Study Information
pubmed
1991
10.2527/1991.6931133x